Dr. Busch is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1365 Washington Ave
Ste 300
Albany, NY 12206Phone+1 518-489-4704Fax+1 518-489-0512
Education & Training
- Albany Medical CenterFellowship, Endocrinology, Diabetes, and Metabolism, 1984
- N Shore U1981
- Zucker School of Medicine at Hofstra/NorthwellInternship, Internal Medicine, 1978 - 1979
- Perelman School of Medicine at the University of PennsylvaniaClass of 1978
Certifications & Licensure
- NY State Medical License 1979 - 2026
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Endocrinology, Diabetes and Metabolism
Awards, Honors, & Recognition
- Hudson Valley Magazine Castle Connolly, 2012-2013
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
- Fellow (FACE) American Association of Clinical Endocrinology
Clinical Trials
- Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus Start of enrollment: 2010 Jun 18
- A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD) Start of enrollment: 2012 Jul 01
- Study to Evaluate the Effects of BMS-813160 on Protein Loss in the Urine of Subjects With Type 2 Diabetes and Diabetic Kidney Disease Start of enrollment: 2013 Mar 18
Publications & Presentations
PubMed
- 366 citationsDulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trialKatherine R. Tuttle, Mark Lakshmanan, Brian Rayner, Robert S. Busch, Alan G. Zimmermann
The Lancet. Diabetes & Endocrinology. 2018-08-01 - 189 citationsSemaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial.Bernard Zinman, Vaishali Bhosekar, Robert S. Busch, Ingrid Holst, Bernhard Ludvik
The Lancet. Diabetes & Endocrinology. 2019-05-01 - 36 citationsCombination SGLT2 inhibitor and GLP-1 receptor agonist therapy: a complementary approach to the treatment of type 2 diabetes.Robert S. Busch, Michael P. Kane
Postgraduate Medicine. 2017-06-28
Press Mentions
- Endocrinology Clinical Trials Program ThrivingMay 4th, 2022
- 50 Things Doctors Would Tell Their Own MothersAugust 9th, 2019
- Diabetes Increases the Risk of Heart Failure More in Women Than in MenJuly 22nd, 2019
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: